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HEPES and MES buffer
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Abstract
Background: In single photon emission computed tomography [SPECT], high specific activity of 111In-labelled
tracers will allow administration of low amounts of tracer to prevent receptor saturation and/or side effects. To
increase the specific activity, we studied the effect of the buffer used during the labelling procedure: NaAc, NH4Ac,
HEPES and MES buffer. The effect of the ageing of the 111InCl3 stock and cadmium contamination, the decay
product of 111In, was also examined in these buffers.
Methods: Escalating amounts of 111InCl3 were added to 1 μg of the diethylene triamine pentaacetic acid [DTPA]-
and 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid [DOTA]-conjugated compounds (exendin-3, octreotide
and anti-carbonic anhydrase IX [CAIX] antibody). Five volumes of 2-(N-morpholino)ethanesulfonic acid [MES], 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid [HEPES], NH4Ac or NaAc (0.1 M, pH 5.5) were added. After 20 min at
20°C (DTPA-conjugated compounds), at 95°C (DOTA-exendin-3 and DOTA-octreotide) or at 45°C (DOTA-anti-CAIX
antibody), the labelling efficiency was determined by instant thin layer chromatography. The effect of the ageing
of the 111InCl3 stock on the labelling efficiency of DTPA-exendin-3 as well as the effect of increasing concentrations
of Cd2+ (the decay product of 111In) were also examined.
Results: Specific activities obtained for DTPA-octreotide and DOTA-anti-CAIX antibody were five times higher in MES
and HEPES buffer. Radiolabelling of DTPA-exendin-3, DOTA-exendin-3 and DTPA-anti-CAIX antibody in MES and HEPES
buffer resulted in twofold higher specific activities than that in NaAc and NH4Ac. Labelling of DTPA-exendin-3
decreased with 66% and 73% for NaAc and NH4Ac, respectively, at day 11 after the production date of
111InCl3, while
for MES and HEPES, the maximal decrease in the specific activity was 10% and 4% at day 11, respectively. The presence
of 1 pM Cd2+ in the labelling mixture of DTPA-exendin-3 in NaAc and NH4Ac markedly reduced the labelling efficiency,
whereas Cd2+ concentrations up to 0.1 nM did not affect the labelling efficiency in MES and HEPES buffer.
Conclusions: We showed improved labelling of DTPA- and DOTA-conjugated compounds with 111In in HEPES and
MES buffer. The enhanced labelling efficiency appears to be due to the reduced competitive chelation of
cadmium. The enhanced labelling efficiency will allow more sensitive imaging of the biomarkers with SPECT.
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Introduction
Radiolabelled peptides and antibodies are used for
molecular imaging and radionuclide therapy of
tumours. The most successful example of peptide
receptor imaging is the somatostatin analogue octreo-
tide, which targets the somatostatin receptor subtype
2, overexpressed on neuroendocrine tumours. Tracers
labelled with a radiometal via a chelator have the
advantage that they can be labelled with high efficiency
(> 95%) without the need for post-labelling purification
and that the metabolites are trapped in the lysosomes
of the cell, leading to higher accumulation in the target
cell. This phenomenon is referred to as ‘metabolic
trapping’ [1-5]. Ideally, low peptide or protein doses
are administered because high doses may lead to
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saturation of the receptor, resulting in reduced accu-
mulation of the radiotracer in the target tissue [6].
In addition, higher doses may cause toxic side
effects, especially when agonists are used. In order to
administer activity doses sufficient for imaging (sin-
gle photon emission computed tomography or planar
scintigraphy), tracers with a high specific activity
[SA] are required. There is a need to further increase
the SA to improve image quality, especially in the
preclinical setting. In general, the tracer doses admi-
nistered in rodent models must be kept low while at
the same time administering relatively high activity
doses (> 10 MBq/animal). 111In is a widely used
radionuclide for the labelling of peptides and pro-
teins used for imaging purposes. To enable labelling
with a radiometal, such as 111In, the targeting mole-
cule has to be conjugated with a chelator. The most
commonly used chelators are diethylene triamine
pentaacetic acid [DTPA] and 1,4,7,10-tetraazacyclo-
dodecane-1,4,7,10-tetraacetic acid [DOTA]. Labelling
of DTPA- and DOTA-conjugated compounds is a
one-step reaction in which the conjugated compound
is incubated with 111InCl3 in a slightly acidic buffer,
keeping the pH between 4 and 5.5. Acetate buffers
are commonly used as a buffer for 111In-labelling of
DTPA- and DOTA-conjugated compounds. Acetate
buffers readily form coordination complexes with
metals. It is assumed that coordinating buffers are
needed for efficient chelation of radiometals [7].
However, for 68Ga-labelling of DOTA-conjugated
compounds, 4-(2-hydroxyethyl)-1-piperazineethane-
sulfonic acid [HEPES] is successfully used as a buf-
fer. Although developed for biological purposes by
Good et al., HEPES has beneficial characteristics in
chemistry involving metal ions as a non-coordinating
buffer [8]. 2-(N-morpholino)ethanesulfonic acid
[MES] was also described as a ‘good buffer’ [8] and
has similar characteristics. Although HEPES and
MES were described as non-coordinating buffers,
recent reports showed that HEPES forms weak com-
plexes with Cu(II) and Pb(II), but not with Zn(II) or
Cd(II) [9,10]. Therefore, the term ‘weakly coordinat-
ing’ buffers seems to be more appropriate.
The fact that HEPES is successfully used for labelling
of compounds with 68Ga prompted us to examine the
effect of the weakly coordinating buffers, HEPES and
MES, on the 111In-labelling and compared this with the
radiolabelling in routinely used acetate buffer (sodium
acetate and ammonium acetate). For comparison of the
radiolabelling in these buffers, two peptides, exendin-3
and octreotide, and the chimeric monoclonal antibody
[mAb] targeting carbonic anhydrase IX [CAIX], each
conjugated with DTPA or DOTA, were used.
Experimental procedures
Peptides and antibodies and conjugation with DTPA or
DOTA
DTPA-Tyr3-octreotide, DOTA-Tyr3-octreotide, [Lys40
(DTPA)]exendin-3 [DTPA-exendin-3] and [Lys40
(DOTA)]exendin-3 [DOTA-exendin-3] [11] were pur-
chased from Peptide Specialty Laboratories GmbH (Hei-
delberg, Germany). The chimeric mAb anti-CAIX
(cG250) was obtained from Wilex AG (Munich, Ger-
many). The conjugation of anti-CAIX with SCN-Bz-
DTPA or SCN-Bz-DOTA (Macrocyclics, Dallas, TX,
USA) with a 50-fold molar excess was performed in a
0.1 M NaHCO3 buffer, with a pH of 8.2. After 1-h incu-
bation, the conjugation mixture was dialyzed in a dialy-
sis cell with a molecular cut-off value of 20 kD (Slide-a-
lyzer, Pierce, Rockford, IL, USA) against 0.25 M ammo-
nium acetate (pH 5.5) with five buffer changes to
remove the unconjugated SCN-Bz-DTPA and SCN-Bz-
DOTA. After conjugation, the protein concentration
was determined spectrophotometrically (Amersham
Pharmacia Biotech, Uppsala, Sweden) at 280 nm. The
substitution ratio was determined by the labelling of the
conjugation mixture with 111InCl3 (Covidien, Petten,
The Netherlands) described by Hnatowich et al. [12].
After incubation at room temperature [RT] for 20 min,
quality control was performed on silica-gel instant thin
layer chromatography [ITLC] strips (ITLC-SG, Biodex
Medical Systems, Inc., Shirley, NY, USA) with sodium
citrate, with a pH of 5.5, as the mobile phase (retention
factor [Rf]
111In-labelled anti-CAIX mAb = 0, Rf
111In-
DTPA or 111In-DOTA = 1). The substitution ratio is
represented by the percentage of activity with an Rf of 0
when the conjugation mixture is labelled.
Buffers
Sodium acetate (Merck, Darmstadt, Germany) was dis-
solved in distilled water (Versol, Lyon, France) to a final
concentration of 0.1 M, and the pH was adjusted to 5.5
by titration with 1 M HCl (Merck, Darmstadt, Ger-
many). Ammonium acetate buffer was prepared by mix-
ing equal volumes of 0.2 M acetic acid (Merck,
Darmstadt, Germany) and 0.2 M ammonia (Merck,
Darmstadt, Germany), and the pH was adjusted to 5.5
by adding 0.2 M acetic acid or 0.2 M ammonia. MES
and HEPES (Sigma-Aldrich Corporation, St. Louis, MO,
USA) were dissolved in distilled water to a final concen-
tration of 0.1 M, and the pH was adjusted to 5.5 with 1
M NaOH (Merck, Darmstadt, Germany).
111In-labelling of peptides and antibodies
The labelling of the six compounds with 111In was per-
formed 9 days after 111In production (The calibration
date of 111InCl3 is 10 days after the production of
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111InCl3, and the expiry date of
111InCl3 is 11 days after
the production of 111InCl3). The peptides and antibodies
were dissolved in metal-free water to a final concentra-
tion of 0.1 μg/μl, and 5 μl was added to a 0.1 M NaAc,
NH4Ac, MES or HEPES buffer. Five volumes of buffer
and one volume of 111InCl3 (Covidien, Petten, The
Netherlands) were added. The reaction mixtures were
incubated for 20 min at RT for DTPA-conjugated com-
pounds, at 95°C for DOTA-exendin and DOTA-octreo-
tide or at 45°C for the DOTA-conjugated anti-CAIX
antibody. After incubation, Tween80 (Sigma-Aldrich
Corporation, St. Louis, MO, USA) was added to a final
concentration of 0.1%, and ethylenediaminetetraacetic
acid [EDTA] (Sigma-Aldrich Corporation, St. Louis,
MO, USA) in 0.25 M NH4Ac, with a pH of 5.5, was
added to a final concentration of 5 mM to complex
unincorporated 111In. Quality control was performed on
silica-gel ITLC strips with 0.1 M EDTA in 0.1 M
NH4Ac as a mobile phase (Rf
111In-labelled compounds
= 0, Rf
111In-EDTA = 1). The maximum SA was deter-
mined by correcting the initial SA for the radiochemical
purity.
Effect of ageing of the 111InCl3 stock on the labelling
efficiency of DTPA-exendin-3
DTPA-exendin-3 (0.5 μg) was labelled in triplicate
(except for t = 14, which is in duplicate) with 111In (75
MBq) in 0.1 M NaAc, NH4Ac, MES and HEPES, with a
pH of 5.5, as described above, from 4 days after the pro-
duction date (delivery of 111InCl3) until 14 days after the
production date of 111InCl3. Quality control was per-
formed as described above.
Effect of the presence of cadmium on the labelling
efficiency of DTPA-exendin-3
The effect of cadmium, the decay product of 111In, on
the radiolabelling was examined by adding increasing
amounts of Cd2+ to the labelling mixture of DTPA-
exendin-3. CdCl2 (Sigma-Aldrich Corporation, St. Louis,
MO, USA) was dissolved in 0.1 M Ultrapure HCl (J.T.
Baker, Deventer, The Netherlands), and serial dilutions
ranging from 10-1 to 10-7 M CdCl2 in 0.02 M HCl were
prepared. DTPA-exendin-3 (0.5 μg) was labelled with
1.85 MBq 111InCl3 (at day 9 after
111InCl3 production)
in 0.1 M NaAc, NH4Ac, MES and HEPES, with a pH of
5.5, as described above, and various amounts of CdCl2
were added simultaneously with 111InCl3 to amounts
ranging from 1 × 10-3 to 9 × 104 nmol (resulting in final
concentrations of Cd2+ ranging from 1 pM to 8.3 μM).
The amount of buffer was adjusted for the amount of
CdCl2 in 0.02 M HCl added (final pH 5.5). The experi-
ment was performed in triplicate for all CdCl2 concen-
trations and all buffers. Quality control was performed
as described above.
Results
Substitution ratio of DTPA- and DOTA-anti-CAIX
The substitution ratio of DTPA- and DOTA-anti-CAIX
was 3 DTPA and 7 DOTA molecules per antibody
molecule, respectively.
Effect of the buffer on the labelling efficiency of DTPA
conjugates
The labelling efficiency at different specific activities of
DTPA-exendin-3, DTPA-octreotide and DTPA-anti-
CAIX in 0.1 M NaAc, NH4Ac, MES and HEPES is
summarized in Figure 1. The maximum specific activ-
ities of the compounds in different buffers were calcu-
lated and are shown in Figure 2 and Table 1. Labelling
of DTPA-exendin-3 in NaAc buffer resulted in a maxi-
mal SA of 379 ± 16 MBq/nmol. The SA was somewhat
lower when DTPA-exendin-3 was labelled in NH4Ac,
207 ± 20 MBq/nmol. Two- to fourfold higher specific
activities were observed when DTPA-exendin-3 was
labelled in MES or HEPES (717 ± 29 and 837.3 ± 6
MBq/nmol, respectively). Similar results were observed
for the labelling of DTPA-octreotide and DTPA-anti-
CAIX (Figures 1 and 2, Table 1).
When DTPA-exendin-3 was labelled in MES, the SA
was 42 ± 2% of the maximum theoretical SA (Figure 3).
Labelling of DTPA-exendin-3 in HEPES resulted in a
SA that was 49 ± 1% of the maximum theoretical SA
and was higher than the SA in acetate buffers (NaAc 22
± 1% and NH4Ac 12 ± 1%). Similar results were
obtained for the labelling of the anti-CAIX antibody,
whereas the overall complexation of 111In by DTPA-
octreotide was somewhat lower for all buffers.
Effect of the buffer on the labelling efficiency of DOTA
conjugates
The SA for 111In-DOTA-exendin-3 was lower than
that of 111In-DTPA-exendin-3 (Figure 2 and Table 1).
However, the same trend was observed: Labelling in
MES and HEPES resulted in higher SA (56 ± 4 and 38
± 16 MBq/nmol) compared to that in the acetate buf-
fers (NaAc 23 ± 8 MBq/nmol and NH4Ac 22 ± 1
MBq/nmol), with the exception that MES performed
better than HEPES in these experiments (Figures 1 and
2, Table 1). Also, for DOTA-anti-CAIX, higher SA
were observed in MES and HEPES buffer, 947 ± 44
and 1,018 ± 7 MBq/nmol, respectively, versus 330 ± 87
MBq/nmol for NaAc and 254 ± 2 MBq/nmol for
NH4Ac (Figures 1 and 2, Table 1). No difference in
specific activities was observed for DOTA-octreotide
(Figures 1 and 2, Table 1).
The complexation of 111In by DOTA-conjugated com-
pounds was less efficient than that by DTPA-conjugated
compounds (Figure 3). The most efficient complexation
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Figure 1 111In-labelling. 111In-labelling of DTPA-exendin-3, DOTA-exendin-3, DTPA-octreotide, DOTA-octreotide, DTPA-anti-CAIX and DOTA-anti-
CAIX in 0.1 M NaAc, NH4Ac, MES and HEPES buffers.
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Figure 2 Maximal specific activities. Maximal specific activities (in megabecquerel per nanomole) for DTPA-exendin-3, DOTA-exendin-3, DTPA-
octreotide, DOTA-octreotide, DTPA-anti-CAIX and DOTA-anti-CAIX in 0.1 M NaAc, NH4Ac, MES and HEPES buffers.
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of 111In was achieved by the labelling of DOTA-anti-
CAIX in HEPES buffer, 8.2 ± 0.1% of the DOTA che-
lates complexed an 111In atom. Labelling in HEPES buf-
fer resulted in similar complexation efficiency (7.6 ±
0.4%), whereas labelling in acetate buffers resulted in a
three to fivefold reduction in the percentage of DOTA
molecules complexed (NaAc 2.7 ± 0.7 and NH4Ac 1.6 ±
0.4). Incorporation of 111In was also more efficient in
HEPES and MES buffer for DOTA-exendin-3, but no
differences in complexation efficiency were observed
when DOTA-octreotide was labelled.
Effect of ageing of the 111InCl3 stock on the labelling
efficiency of DTPA-exendin-3
The effect of ageing of the 111InCl3 stock on the labelling
efficiency of DTPA-exendin-3 in 0.1 M NaAc, NH4Ac,
MES and HEPES was investigated, and the results are sum-
marized in Figures 4 and 5. Four days after the production
of 111InCl3 (arrival of
111InCl3 stock), DTPA-exendin-3
could be labelled with 111In with similar labelling efficiency,
resulting in similar SA, for all buffers. In NaAc and NH4Ac,
a reduced labelling efficiency was observed as soon as 7
days after the production of 111InCl3, decreasing to a label-
ling efficiency of 34 ± 8% and 27 ± 3% for NaAc and
NH4Ac, respectively at day 11. Only a minimal decrease in
labelling efficiency was observed when the labelling was
performed in MES buffer: from 92.6 ± 5.2% at day 4 to 78.3
± 3.0% at day 14. A decrease in labelling efficiency was not
observed up to day 9. The time point of radiolabelling did
not have any significant effect on the labelling efficiency or
SA when HEPES was used for the radiolabelling. Labelling
in HEPES at day 4 resulted in a labelling efficiency of 87 ±
7% with a SA 627 ± 54 MBq/nmol. A labelling efficiency of
92 ± 6% and a SA of 625 ± 54 MBq/nmol were obtained at
day 14 after the production date of 111InCl3. These results
were not significantly different from the results obtained 4
days after the production date.
Effect of the presence of cadmium on the labelling
efficiency of DTPA-exendin-3
In Figure 6 and Table 2 the effect of the Cd2+ concen-
tration in the labelling mixture on the labelling
efficiency of DTPA-exendin-3 is summarized. A
decrease in labelling efficiency was observed when 1 pM
CdCl2 was added to the labelling of DTPA-exendin-3
with 111In in NaAc and NH4Ac, whereas up to 0.1 nM
Cd2+ did not affect the labelling efficiency when DTPA-
exendin-3 was labelled in MES or HEPES.
The Cd2+ concentration that lead to a 50% reduction
in labelling efficiency was lower in NaAc (0.011 nM,
95% confidence interval 0.007 to 0.019 nM) and NH4Ac
(0.013 nM, 95% confidence interval 0.010 to 0.019 nM)
than that in MES (2.5 nM, 95% confidence interval 1.5
to 4.1 nM) and HEPES (2.7, 95% confidence interval 2.2
to 3.3 nM), indicating that the labelling efficiency was
not affected by Cd2+ contamination in MES and HEPES
buffer.
Discussion
High SA of 111In-labelled peptides and antibodies is
required to administer a tracer dose of peptide or pro-
tein, preventing target saturation and/or side effects,
while administering high activity doses required for ima-
ging. Acetate buffers are routinely used for the labelling
of DTPA- and DOTA-conjugated compounds with
111In. Here, we examined the effect of the buffer used
during the radiolabelling: HEPES and MES, and com-
pared this with the most commonly used acetate buffers:
sodium acetate and ammonium acetate, and showed
that an increased SA could be obtained when DTPA-
and DOTA-conjugated compounds were labelled in
MES or HEPES buffer. Moreover, the labelling efficiency
was not affected by Cd2+ concentrations up to 0.1 nM
when the labelling was performed in MES and HEPES,
whereas a drastic effect was observed when the labelling
was performed in acetate buffers. In line with these
results, the ageing of the 111InCl3 stock had only a
minor effect on the labelling efficiency 14 days after the
production of 111InCl3 when compounds were labelled
in MES and HEPES.
The use of MES as a buffer for radiolabelling resulted
in a SA of all DTPA-conjugated compounds that was
approximately two to three times higher when com-
pared to radiolabelling in ammonium acetate and
Table 1 Maximal specific activities of DTPA- and DOTA-conjugated compounds
Compound NaAc (MBq/nmol)a NH4Ac (MBq/nmol)
a MES (MBq/nmol)a HEPES (MBq/nmol)a Maximum theoretical SAb (GBq/nmol)
DTPA-exendin-3 379 ± 16 207 ± 20 717 ± 29 837 ± 6 1.7
DTPA-octreotide 95 ± 5 52 ± 4 248 ± 24 650 ± 10 1.7
DTPA-cG250 338 ± 60 246 ± 37 835 ± 46 939 ± 50 5.2
DOTA-exendin-3 23 ± 8 22 ± 1 56 ± 4 38 ± 16 1.7
DOTA-octreotide 38 ± 0 39 ± 0 39 ± 0 39 ± 0 1.7
DOTA-cG250 330 ± 87 254 ± 2 947 ± 44 1018 ± 7 12.4
aMaximal specific activities (in megabecquerel per nanomole) and the bmaximum theoretical SA (in gigabecquerel per nanomole) for DTPA-exendin-3, DOTA-
exendin-3, DTPA-octreotide, DOTA-octreotide, DTPA-anti-CAIX and DOTA-anti-CAIX in 0.1-M NaAc, NH4Ac, MES and HEPES buffers. The maximum theoretical SA is
calculated, assuming that 1 nmol DTPA or DOTA can complex 1 nmol 111In.
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Figure 3 Percentage of the maximum theoretical SA. Percentage of the maximum theoretical SA of DTPA-exendin-3, DOTA-exendin-3, DTPA-
octreotide, DOTA-octreotide, DTPA-anti-CAIX and DOTA-anti-CAIX in 0.1 M NaAc, NH4Ac, MES and HEPES buffers.
Brom et al. EJNMMI Research 2012, 2:4
http://www.ejnmmires.com/content/2/1/4
Page 7 of 11
sodium acetate, respectively. When HEPES was used, an
even higher SA of the DTPA-conjugated compounds
was observed: four times higher than the labelling per-
formed in ammonium acetate. The effect was less pro-
nounced when the DOTA-conjugated compounds were
labelled with 111In. Overall, radiolabelling in HEPES and
MES was more efficient than that in acetate buffers in
most cases and at least as efficient as in the case of
DOTA-octreotide. Labelling of DOTA-conjugated com-
pounds resulted in 5 to 20 times lower SA than that of
DTPA-conjugated compounds. Most likely, this is due
to the interference of contaminating metals with DOTA
chelation, which might play a role to a lesser extent
when labelling DTPA-conjugated compounds.
The decay product of 111In, 111Cd, can also be che-
lated by DTPA or DOTA, and it is therefore expected
that the complexation of 111In is less efficient over time
due to increasing amounts of Cd2+. Indeed, this phe-
nomenon was observed when sodium acetate and
ammonium acetate were used for the 111In-labelling of
DTPA-exendin. Lower labelling efficiencies were
observed as early as 7 days after the production of
111InCl3, and threefold lower SA were obtained when
the labelling was performed with 111InCl3 11 days after
the production date. This effect was not observed for
the labelling of DTPA-exendin-3 in MES and HEPES
with a maximal decrease in SA of 10% and 4% at day
11, respectively. Even the decrease in SA 14 days after
the calibration date of 111InCl3 was not more than 18%
for 111In-labelling in MES and 5% for HEPES. These lat-
ter results could explain the differences in SA of the six
compounds used in this study since the labelling of
these compounds was performed with 111In 9 days after
production. Generally, 111InCl3 is used from 7 to 11
Figure 4 Radiolabelling of DTPA-exendin-3 with 111In. Radiolabelling of DTPA-exendin-3 with 111In at different time points from the
production (day 0) of 111InCl3 for 0.1 M NaAc, NH4Ac, MES and HEPES. Asterisk, labelling performed in duplicate; double asterisks, single labelling
performed.
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Figure 5 Maximal SA of 111In-DTPA-exendin-3 at several time points after 111InCl3 production (t = 1 day). The SA was calculated by the
initial SA (712 MBq/nmol) corrected by the labelling efficiency. Asterisk, labelling performed in duplicate; double asterisks, single labelling
performed.
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days after the production day, which could lead to
reduced specific activities at later time points when acet-
ate buffers are used. To overcome this problem, HEPES
or MES buffer could be used for radiolabelling, with
high specific activities at time points up to 14 days after
111InCl3 production. This could have an impact on
experiment planning since experiments which require
high-SA-labelled compounds are only available early
after 111In production when acetate buffers are used,
whereas the time point is not relevant when MES or
HEPES is used. These results suggest that increasing
amounts of Cd2+ contamination, due to the ageing of
the 111InCl3 stock, do not influence the labelling of
DTPA-conjugated compounds when MES and HEPES
are used as a buffer for radiolabelling.
The suggested effect of cadmium on the 111In-label-
ling of DTPA-conjugated compounds was confirmed
when increasing amounts of Cd2+ were added to the
111In-labelling mixture of DTPA-exendin. In HEPES and
MES buffer, a 100-fold higher amount of cadmium
could be added to the labelling mixture without redu-
cing the labelling efficiency than in acetate buffer. The
decreased labelling efficiency at low concentrations of
cadmium might be due to the efficient formation of
coordination complexes of Cd2+ with acetate, allowing
efficient ‘transchelation’ of Cd2+, whereas no coordina-
tion complex with HEPES or MES is formed [9], and
transchelation of Cd2+ to DTPA or DOTA is less
efficient.
It has been postulated that coordination complex
formation of 111In with acetate buffers is necessary for
efficient labelling of DTPA- and DOTA-conjugated
compounds [13] since it is assumed that the coordina-
tion complex formation prevents the formation of
insoluble 111In-hydroxide. This study suggests that
Figure 6 Effect of cadmium on labelling of 111In-DTPA-exendin-3 in 0.1 M NaAc, NH4Ac, MES and HEPES.
Table 2 50% Inhibitory concentration of cadmium on the
111In-labelling of DTPA-exendin-3
Buffer 50% inhibitory concentration of Cd2+ (nM)a
NaAc 0.011 (0.007 to 0.019)
NH4Ac 0.013 (0.010 to 0.019)
MES 2.5 (1.5 to 4.1)
HEPES 2.7 (2.2 to 3.3)
aCadmium concentrations that lead to a 50% reduction in the labelling
efficiency of DTPA-exendin-3 in 0.1 M NaAc, NH4Ac, MES and HEPES. The 95%
confidence interval is indicated in parentheses.
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coordination complex formation of the buffer with 111In
is less important for efficient labelling of DTPA- and
DOTA-conjugated compounds since the labelling in the
weakly coordinating buffers MES and HEPES was more
efficient than that in acetate buffers in most cases or at
least equivocal in the case of DOTA-octreotide.
Breeman et al. described the effect of contaminants on
the labelling of DOTA-octreotide with 111In, 177Lu and
90Y, and found a similar result of the effect of cadmium
contamination on the radiolabelling [14]. The labelling
procedures described in the latter study were performed
in sodium acetate, and these findings are in line with
the findings in our study, where a pronounced effect of
Cd2+ on the labelling of DTPA-exendin-3 is observed
when sodium acetate is used as buffer for radiolabelling.
The purification of 111InCl3 by an anion exchange
method was described to improve the labelling of
DTPA- and DOTA-conjugated compounds caused by
the removal of contaminants, mainly Cd2+, present in
the 111InCl3 solution [15]. By using HEPES or MES buf-
fer for the labelling of the compounds, this could omit a
time-consuming purification method.
Conclusions
We showed improved labelling of DTPA- and DOTA-
conjugated peptides, proteins and antibodies with 111In
when HEPES or MES buffer was used for radiolabelling.
The enhanced labelling efficiency could be due to the
reduced competitive chelation of cadmium, the decay
product of 111In. When 111In-labelling of DTPA- and
DOTA-conjugated compounds is performed in MES or
HEPES, 111In-labelled compounds can be produced with
high specific activities regardless from the time point
after 111In production.
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